Table 1.
Clinical Characterization of Participating Control and Asthma Patients
| Age | Subject Type | Gender | Nasal Steroid | Inhaled Steroid | ACT™ score | FEV1 (% predicted) | FENO (ppb) | Sputum Eosinophil (% non-squamous cells) | Sputum EPX (ng/mL-g protein) | Nasal EPX (ng/mg protein) | Pharyngeal EPX (ng/mg protein) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 61 | Asthma | Male | Y | Y | 17 | 72 | 53 | 4.3 | 532 | 46 | 24 |
| 53 | Asthma | Male | Y | Y | 5 | 57 | 141 | 45.5 | 806 | 57 | 74 |
| 52 | Asthma | Female | - | - | 11 | 57 | 77 | 62.7 | 369 | 58 | 22 |
| 50 | Asthma | Female | Y | Y | 10 | 69 | 73 | 48 | 20196 | 151 | 76 |
| 46 | Asthma | Male | - | - | 8 | 75 | 175 | 8 | 191 | 446 | 39 |
| 56 | Asthma | Male | - | Y | 12 | 37 | 104 | 5 | 247 | 59 | 274 |
| 38 | Asthma | Male | - | - | 9 | 43 | 70 | 0.5 | 1735 | 1 | 1.63 |
| 42 | Asthma | Female | - | Y | 10 | 66 | 70 | 7.8 | 106 | 16 | 303 |
| 47 | Asthma | Female | - | - | 12 | 99 | 115 | 48 | 139 | 182 | 469 |
| 32 | Asthma | Female | - | Y | 8 | 65 | 52 | 70.8 | 2374 | 1026 | 33487 |
| 25 | Control | Female | - | - | NP | 124 | NP | 0.75 | 6 | 0 | 0 |
| 36 | Control | Female | - | - | NP | 105 | NP | 0.3 | NA | 0 | 15 |
| 37 | Control | Female | - | - | NP | 99 | NP | NA | NA | 5 | 80 |
| 36 | Control | Female | - | - | NP | 97 | NP | NA | NA | 1 | 0.49 |
| 63 | Control | Male | - | - | NP | 91 | NP | NA | NA | 5 | 80 |
| 44 | Control | Male | - | - | NP | 107 | NP | NA | NA | 127 | 17 |
| 58 | Control | Male | - | - | NP | 100 | NP | 0 | 167 | 5 | 0 |
| 56 | Control | Male | - | - | NP | 104 | NP | NA | NA | 1 | 0.13 |
| 25 | Control | Male | - | - | NP | 89 | NP | 0.5 | 183 | 2 | 0 |
| 52 | Control | Female | - | - | NP | 96 | NP | 0 | 48 | 2 | 0 |
NA = Not Available
NP = Not Performed
Y = Yes
-= No